In addition to their effects on type 2 diabetes, weight loss and colorectal cancer risk, glucagon-like peptide-1 receptor analogues may also act on nine other obesity-related cancers, reports a new study.
Much of the focus for proactive treatments for patients with diabetes has been on type 2 diabetes. But what can be done for patients at risk of developing type 1 diabetes?